The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a significant substantial loss in body size and improve metabolic markers, particula